Fig. 1.
Pimozide treatment exacerbated motor performance in TDP-43A315T mice. TDP-43A315T mice were treated at 9 months of age with intraperitoneal injection of 1-mg/kg pimozide (n = 12) or vehicle (n = 8) every 2 days and followed for 4 months. Data were analyzed by two-way ANOVA followed by uncorrected Fisher’s LSD post hoc test. (a) Body weight analysis of animals showed no differences between treatments (two-way ANOVA analysis: interaction p > 0.05, time p < 0.0001, treatment p > 0.05). (b) Rotarod test revealed significant differences between pimozide- and vehicle-injected mice starting from the beginning of the treatment (two-way ANOVA analysis: interaction p > 0.05, time p > 0.05, treatment p < 0.0001). (c) No significant differences were observed for grip strength test (two-way ANOVA analysis: interaction p > 0.05, time p < 0.0001, treatment p > 0.05). Data are expressed as mean ± sem of percentage of maximum performance for each single mouse